Sterling Capital Management’s Denali Therapeutics DNLI Stock Holding History

Sterling Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73K	Sell	2,837 -1,656	-37%	-$34K	﹤0.01%	1484
2026 Q1	$86.3K	Sell	4,493 -2,745	-38%	-$54.6K	﹤0.01%	1439
2025 Q4	$119K	Sell	7,238 -1,416	-16%	-$23.9K	﹤0.01%	1459
2025 Q3	$126K	Buy	8,654 +5,268	+156%	+$75.7K	﹤0.01%	1461
2025 Q2	$47.4K	Buy	3,386 +2,397	+242%	+$33.7K	﹤0.01%	1521
2025 Q1	$13.4K	Sell	989 -784	-44%	-$15K	﹤0.01%	1776
2024 Q4	$36.1K	Buy	1,773 +1,516	+590%	+$38.8K	﹤0.01%	1704
2024 Q3	$7.49K	Buy	+257	New	+$6.37K	﹤0.01%	1627

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's DNLI Position: Q2 2026 in Review

Sterling Capital Management reduced its Denali Therapeutics (DNLI) stake by 37% in Q2 2026, selling an estimated $34K and leaving 2,837 shares worth $73K. The position accounts for ﹤0.01% of the portfolio, ranked #1484.

Sterling Capital Management first reported a position in DNLI in Q3 2024 and has held it in 8 quarters since. The position peaked at $126K in Q3 2025. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Sterling Capital Management held 2,837 shares of Denali Therapeutics worth $73K as of Q2 2026.
Sterling Capital Management sold 1,656 Denali Therapeutics shares in Q2 2026, an estimated $34K.
Denali Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1484 holding.
Sterling Capital Management first reported a position in Denali Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Denali Therapeutics position peaked at $126K in Q3 2025.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.